

RECEIPT

B0801/7187 (ERP/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
FILING RECEIPT  
Applicant: Michael B. Brenner et al.  
Serial No.: 09/654,328  
Filed: September 1, 2000  
For: METHODS AND COMPOSITIONS FOR TREATMENT OF  
INFLAMMATORY DISEASE USING CADHERIN-II MODULATING  
AGENTS  
Examiner: Not yet assigned  
Art Unit: 1645

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 19th day of December, 2000.

*E. R. Plumer*  
Elizabeth R. Plumer, Reg. No. : 36,637

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- Request for Corrected Filing Receipt
- Copy of Filing Receipt, corrections in red ink
- Return Postcard

If the enclosed papers are considered incomplete, the U.S. Patent and Trademark Office is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No check is enclosed. Please charge any underpayment to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,


*E. R. Plumer*  
Elizabeth R. Plumer, Reg. No. 36,637  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No.: B0801/7187(ERP/MAT)

Date: December 19, 2000

xndd

RECEIVED  
MURKIN, GREENFIELD & SACKS, P.C.  
DECEMBER 19 2000  
MR. 2 2001




B0801/7187 (ERP/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael B. Brenner et al.  
Art. No.: 09/654,328  
Filed: September 1, 2000  
For: METHODS AND COMPOSITIONS FOR TREATMENT OF  
INFLAMMATORY DISEASE USING CADHERIN-II MODULATING  
AGENTS  
Examiner: Not yet assigned  
Art Unit: 1645

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 19th day of December, 2000.

  
Elizabeth R. Plumer, Reg. No. : 36,637

Commissioner for Patents  
Washington, D.C. 20231

**SECOND REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

Applicants respectfully request a corrected filing receipt for the above-identified patent application.


In the Continuing Data as Claimed by Applicant data:

Please delete [AND CLAIMS BENEFIT OF 60/152,456 09/03/1999]

Enclosed is a copy of the filing receipt with the desired changes marked in red ink.

Please send a corrected filing receipt at your earliest convenience. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

Respectfully submitted,

  
Elizabeth R. Plumer, Reg. No. 36,637  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No.: B0801/7187(ERP/MAT)

Date: December 19, 2000

xndd

RECEIVED  
TECH CENTER 1600/2600  
MAR 22 2001  
502157.1

502157.1



## UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT AND TRADEMARK OFFICE

O I P E  
DEC 26 2000  
SCT 103-2000COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.govPage 1 of 4  
*ERP*

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/654,328	09/01/2000	1645	1054	B0801/7187 (ERP/MAT)	8	20	6

Elizabeth R Plumer  
Wolf Greenfield & Sacks P C  
600 Atlantic Avenue  
Boston, MA 02210

## FILING RECEIPT



\*OC000000005596227\*

Date Mailed: 12/05/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Michael B. Brenner, Newton, MA ;  
Xavier Valencia, Gaithersburg, MD ;

09/01/01 (2)

File Folder	Initials
ECB	<input checked="" type="checkbox"/>
Docket Entry	<input checked="" type="checkbox"/>
Docket Cross Off	<input checked="" type="checkbox"/>
Order Copies	<input checked="" type="checkbox"/>
Annuities	<input checked="" type="checkbox"/>
Confirmation	<input checked="" type="checkbox"/>
12/13/00	

## Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/152,456 09/03/1999  
~~AND CLAIMS BENEFIT OF 60/152,456 09/03/1999~~  
AND CLAIMS BENEFIT OF 60/153,490 09/13/1999

## Foreign Applications

If Required, Foreign Filing License Granted 10/17/2000

## Title

Methods and compositions for treatment of inflammatory disease using cadherin modulating agents

## Preliminary Class

435

RECEIVED  
TECH CENTER 1600/2900  
DEC 2 2000

Data entry by : ZIMMERMAN, SHAUNA

Team : OIPE

Date: 12/05/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231